ClearView Diagnostics
ClearView Diagnostics provides AI software that helps radiologists detect breast cancer more quickly. The platform uses deep learning to analyze radiology and ultrasound images as a clinical decision support tool. It has FDA 510(k) clearance for the cCAD product and has pursued NIH-funded studies. The company targets radiology departments and clinics, operating in the B2B software space. Its work aims to scale diagnostic accuracy and reduce healthcare costs across systems.
ClearView Diagnostics
ClearView Diagnostics provides AI software that helps radiologists detect breast cancer more quickly. The platform uses deep learning to analyze radiology and ultrasound images as a clinical decision support tool. It has FDA 510(k) clearance for the cCAD product and has pursued NIH-funded studies. The company targets radiology departments and clinics, operating in the B2B software space. Its work aims to scale diagnostic accuracy and reduce healthcare costs across systems.
TL;DR
Product: AI deep-learning software (ClearView cCAD) for breast cancer detection
Regulatory status: FDA 510(k) clearance for cCAD (January 2017)
Founded: 2012 (July 15, 2012 listed)
Headquarters: Chicago, Illinois, United States
Operating status: Closed (listed as permanently closed on Crunchbase)
Company Overview
Problem Domain
Breast cancer detection; diagnostic imaging accuracy and efficiency in radiology departments and clinics.
Founded
2011
Industry
DeepTech
Tech Stack
Funding Track Record
Last funding round listed as Seed closed on June 1, 2013 (Crunchbase)